Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome:<scp>CALGB</scp>10105 (<scp>A</scp>lliance)
Xiaofeng Wang(Nanjing University of Chinese Medicine), Daryl J. Murry(University of Nebraska Medical Center), Pankaj Gupta(St. Jude Children's Research Hospital), Flora Mulkey(Sherwin Williams (United States)), Mark J. Ratain(University of Chicago), Richard A. Larson(Urbana University), Lionel D. Lewis(Dartmouth College), Antonius A. Miller(Roswell Park Comprehensive Cancer Center), Ravi Vij(Washington University in St. Louis), David D. Hurd(Duke University), Kouros Owzar(Duke University)
Cited by 10
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k